[go: up one dir, main page]

DE69232944D1 - Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren - Google Patents

Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Info

Publication number
DE69232944D1
DE69232944D1 DE69232944T DE69232944T DE69232944D1 DE 69232944 D1 DE69232944 D1 DE 69232944D1 DE 69232944 T DE69232944 T DE 69232944T DE 69232944 T DE69232944 T DE 69232944T DE 69232944 D1 DE69232944 D1 DE 69232944D1
Authority
DE
Germany
Prior art keywords
ige
receptor
specific
binding
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232944T
Other languages
English (en)
Other versions
DE69232944T2 (de
Inventor
M Jardieu
G Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232944(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to DE122006000006C priority Critical patent/DE122006000006I2/de
Application granted granted Critical
Publication of DE69232944D1 publication Critical patent/DE69232944D1/de
Publication of DE69232944T2 publication Critical patent/DE69232944T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69232944T 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren Expired - Lifetime DE69232944T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122006000006C DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07
PCT/US1992/006860 WO1993004173A1 (en) 1991-08-14 1992-08-14 Immunoglobulin variants for specific fc epsilon receptors

Publications (2)

Publication Number Publication Date
DE69232944D1 true DE69232944D1 (de) 2003-04-10
DE69232944T2 DE69232944T2 (de) 2003-12-24

Family

ID=27114350

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69232944T Expired - Lifetime DE69232944T2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69233716T Expired - Lifetime DE69233716T2 (de) 1991-08-14 1992-08-14 Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
DE122006000006C Active DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69233716T Expired - Lifetime DE69233716T2 (de) 1991-08-14 1992-08-14 Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
DE122006000006C Active DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Country Status (11)

Country Link
EP (2) EP1260521B1 (de)
JP (1) JP3457962B2 (de)
AT (1) ATE233813T1 (de)
AU (2) AU2498192A (de)
CA (1) CA2113813C (de)
DE (3) DE69232944T2 (de)
DK (2) DK0602126T3 (de)
ES (2) ES2193136T3 (de)
LU (1) LU91219I2 (de)
NL (1) NL300220I2 (de)
WO (1) WO1993004173A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
EP0589840B1 (de) * 1992-09-24 2004-04-14 Novartis AG Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
EP0739214B1 (de) * 1994-01-18 1998-03-18 Genentech, Inc. Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100584051B1 (ko) * 1996-03-01 2006-05-30 노파르티스 아게 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2002537403A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ＩｇＥのＣ−イプシロン−３またはＣ−イプシロン−４ドメイン由来のエピトープまたはミモトープ、その拮抗薬、及びそれらの治療的使用
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
PT1501369E (pt) 2002-04-26 2015-09-21 Genentech Inc Purificação de proteínas com base na não afinidade
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1558650A2 (de) 2002-11-08 2005-08-03 Ablynx N.V. Antikörper aus camelidae gegen immunoglobulin e und ihre verwendung zur behandlung allergischer erkrankungen
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
PL3095793T3 (pl) 2003-07-28 2020-09-07 Genentech, Inc. Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
WO2007032804A2 (en) 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
BRPI0806367A2 (pt) 2007-01-22 2011-09-06 Genentech Inc métodos de purificação de anticorpos
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2609280T3 (es) * 2007-08-23 2017-04-19 Lsi Medience Corporation Inhibidor de reacción no específica
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
AU2008360625C1 (en) 2008-08-14 2017-01-19 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
CA2734275A1 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
JP2012512244A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質の精製
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
CN102333548B (zh) 2009-02-27 2013-01-30 健泰科生物技术公司 用于蛋白质标记的方法和组合物
AR076640A1 (es) 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
SI2550018T1 (sl) 2010-03-22 2019-05-31 F. Hoffmann-La Roche Ag Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
CN107312062B (zh) 2010-05-17 2021-03-16 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
EP2576580B1 (de) 2010-05-28 2016-09-14 F.Hoffmann-La Roche Ag Senkung eines lactatspiegels und erhöhung einer polypeptidherstellung durch herunterregulierung der expression von lactatdehydrogenase- und pyruvatdehydrogenase-kinase
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR20140004231A (ko) 2011-07-08 2014-01-10 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
EP3492486A1 (de) 2011-12-22 2019-06-05 F. Hoffmann-La Roche AG Verfahren zur verbesserung von proteinreinigungsschritten durch ionenaustauschmembranchromatographie
MY171729A (en) 2012-03-27 2019-10-25 Genentech Inc Improved harvest operations for recombinant proteins
HRP20250525T1 (hr) 2012-05-18 2025-06-20 Genentech, Inc. Visokokoncentrirane formulacije monoklonskog protutijela
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
CA2953154C (en) 2014-07-09 2023-03-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018119312A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
EP3565587A4 (de) * 2017-01-06 2020-12-16 The Regents of The University of California Therapeutische anti-ige-antikörper und verfahren und zusammensetzungen davon
EP3635093A1 (de) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Verbesserte zellkulturverfahren
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CN111315413A (zh) 2017-11-07 2020-06-19 秀比特生物技术公司 通过IgE类特异性免疫反应的抑制效果阻止婴儿期变态反应素质获得的方法
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
US20210380923A1 (en) 2018-10-10 2021-12-09 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
SG11202111349QA (en) 2019-04-12 2021-11-29 Geltor Inc Recombinant elastin and production thereof
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
JP2022550976A (ja) * 2019-10-01 2022-12-06 エプシロゲン エルティーディー ハイブリッド抗体
WO2022007965A1 (zh) 2020-07-10 2022-01-13 上海济煜医药科技有限公司 一种抗IgE的工程化抗体及其应用
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
EP0407392B2 (de) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden

Also Published As

Publication number Publication date
CA2113813A1 (en) 1993-03-04
DE122006000006I2 (de) 2011-06-16
EP1260521A3 (de) 2004-01-02
HK1014542A1 (en) 1999-09-30
AU2498192A (en) 1993-03-16
AU706584C (en) 2003-07-10
EP1260521B1 (de) 2007-11-21
EP0602126A1 (de) 1994-06-22
ATE233813T1 (de) 2003-03-15
DK0602126T3 (da) 2003-06-16
DE69233716T2 (de) 2008-10-30
LU91219I2 (fr) 2006-04-03
CA2113813C (en) 2005-04-12
JPH06509944A (ja) 1994-11-10
NL300220I2 (nl) 2006-08-01
DE69232944T2 (de) 2003-12-24
DK1260521T3 (da) 2008-03-25
HK1050696A1 (en) 2003-07-04
NL300220I1 (nl) 2006-04-03
ES2193136T3 (es) 2003-11-01
DE69233716D1 (de) 2008-01-03
EP0602126B1 (de) 2003-03-05
AU7038096A (en) 1997-01-16
ES2296839T3 (es) 2008-05-01
AU706584B2 (en) 1999-06-17
WO1993004173A1 (en) 1993-03-04
EP1260521A2 (de) 2002-11-27
JP3457962B2 (ja) 2003-10-20
DE122006000006I1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
DE69232944D1 (de) Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69836630D1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
ATE321134T1 (de) Menschlicher fc-gamma-rezeptor iii
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
DE68929545D1 (de) Pollen Allergene
DE69031410D1 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
ES2187946T3 (es) Uso de interleucina-15.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ZA891861B (en) Monoclonal antibodies
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE157401T1 (de) Monoklonale antikörper gegen humanes ige
ATE175209T1 (de) Allergene proteine aus ambrosia und verwendung davon
DE69315341D1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69230614D1 (de) Protein-s polypeptide und deren verwendungen
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
EP0651800A4 (de) Proteine aus granulabasophilen zellen.